Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.
Compounded GLP-1 Guidepricing database · evidence ledger

Newsroom — GLP-1 regulatory & market briefs

Fifteen dated briefs — newest first — on regulatory and market events that change what compounded-GLP-1 buyers face: FDA enforcement and rulemaking, adverse-event reporting, manufacturer price moves, approvals, and coverage changes. Each brief separates event date from publication and update dates, cites primary sources, and carries a change log. Investigational agents receive research-only coverage per the methodology. Last updated: 2026-08-09.

Lilly Q2: tirzepatide passes $27.7B for the half; Foundayo's first quarter lands at $98M

Event date: 2026-08-05 · Published: 2026-08-10 · Discovered: on/around event date · Last updated: 2026-08-10

Eli Lilly's second-quarter report put Mounjaro at $9.94B (+91%) and Zepbound at $4.93B — $27.7B combined for the half — with full-year guidance raised to $85–87B and a reported 60.9% share of the U.S. obesity/diabetes market. Two details matter for cash buyers: realized prices fell ~13% even as volumes surged, and Foundayo's first reported quarter came in at $98M, slightly under estimates, with Lilly framing the oral market as additive rather than cannibalizing Zepbound. Retatrutide remains pipeline-stage with a U.S. filing planned — research-only status unchanged. Self-pay tiers tracked on this site ($299–$449 Zepbound; $149 Foundayo entry) were not changed by the report.

Primary sources: Eli Lilly Q2 2026 release and earnings coverage (Reuters, CNBC, BioPharma Dive), August 5, 2026 · Change log: 2026-08-10 — initial publication.

Novo Q2: CagriSema misses the tirzepatide head-to-head; Wegovy pill underperforms; Germany launch set

Event date: 2026-08-04 · Published: 2026-08-10 · Discovered: on/around event date · Last updated: 2026-08-10

Novo Nordisk's quarter carried three developments. CagriSema failed to match tirzepatide's blood-sugar control in a head-to-head type-2-diabetes trial — its second miss against Lilly's drug this year, sharpening pipeline questions. Oral Wegovy sales missed expectations, with analysts noting the $149 tablet's pricing edge narrowed once the Medicare ~$50 tier flattened copays across drugs. And the Wegovy pill gets its first EU launch, in Germany, in September. Reported guidance commentary also flagged planned U.S. list-price reductions for 2027 (figures around 50% Wegovy / 35% Ozempic in coverage) — treated here as reported plans, not current prices; today's self-pay tiers stand.

Primary sources: Novo Nordisk Q2 2026 results and coverage (CNBC, BioPharma Dive, PharmExec), August 4–6, 2026 · Change log: 2026-08-10 — initial publication.

Additive-interaction research: B12 co-formulation can chemically bond with tirzepatide

Event date: 2026-07 (reported) · Published: 2026-08-10 · Discovered: on/around event date · Last updated: 2026-08-10

A 2026 study reported that when tirzepatide is compounded together with vitamin B12 — a common differentiator additive in compounded GLP-1 products — the two substances can chemically bond, forming a new molecule not found in the FDA-approved drug. Alongside the long-running salt-form concern, this is the clearest evidence yet that "the same active ingredient plus extras" is not a neutral formula. Practical takeaway for buyers: ask whether your preparation contains additives, and prefer plain formulations absent a clinical reason — the additive question now belongs on the pre-purchase checklist.

Primary sources: Stanford Medicine reporting on compounded GLP-1 safety research (July 2026); underlying 2026 formulation study · Change log: 2026-08-10 — initial publication.

Comment period closes on the FDA's 503B bulks proposal

Event date: 2026-06-29 · Published: 2026-08-10 · Discovered: on/around event date · Last updated: 2026-08-10

The public-comment window on the FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list closed at the end of June; a final determination follows the agency's review. If finalized, the rule would formalize the end of large-scale outsourcing-facility compounding of these molecules — while the patient-specific 503A pathway, under which programs tracked here operate, is not the subject of the proposal. Status will be updated here when the agency acts.

Primary sources: Federal Register docket (proposed rule, April 30, 2026; comments through June 29, 2026); FDA compounding pages · Change log: 2026-08-10 — initial publication.

Medicare obesity-medication coverage phase-in reaches the ~$50 copay tier

Event date: 2026-07-01 · Published: 2026-08-09 · Discovered: on/around event date · Last updated: 2026-08-09

Qualifying Medicare patients began accessing covered obesity medications at roughly a $50 monthly copay under the 2026 phase-in — a coverage door that, where it applies, undercuts every cash figure this site tracks, compounded or brand. Coverage is criteria-bound; the practical takeaway for eligible readers is to exhaust coverage checks before shopping the cash market this site documents.

Change log addition (2026-08-10): subsequent reporting around the Q2 earnings cycle identifies the mechanism as a Medicare "GLP-1 Bridge" pilot placing covered obesity medications at a uniform ~$50 monthly copay for eligible beneficiaries — a flat tier across drugs rather than per-product pricing.

Primary sources: CMS/HHS program materials; plan documentation · Change log: 2026-08-09 — initial publication.

FDA adverse-event tally for compounded tirzepatide passes 730 reports

Event date: 2026-05-31 · Published: 2026-08-09 · Discovered: on/around event date · Last updated: 2026-08-09

FDA's running count of adverse-event reports associated with compounded tirzepatide exceeded 730 as of May 31, 2026. Reports are raw, unadjudicated signals without denominators — not a risk rate — but recurring themes (dosing errors with multi-dose vials, product-quality questions) map directly onto the failure modes our vial-math and dosing-error guides exist to prevent. Report problems to FDA MedWatch.

Primary sources: FDA — unapproved GLP-1 concerns · Change log: 2026-08-09 — initial publication.

Retatrutide phase 3 results published (research-only)

Event date: 2026-05-21 · Published: 2026-08-09 · Discovered: on/around event date · Last updated: 2026-08-09

Topline TRIUMPH-1 results reported average weight reductions up to roughly 30% over 80 weeks at the highest dose, with diabetes (TRIUMPH-2) and cardiovascular-population (TRIUMPH-3) results following on 2026-07-23 at up to 20.8% and 22.6% respectively. Research-only coverage: retatrutide is not FDA approved, is not lawfully available as a compounded treatment, and no provider, pricing, or availability content applies; anything sold today under that name is unregulated gray-market material.

Primary sources: Eli Lilly topline releases; peer-reviewed publications as available · Change log: 2026-08-09 — initial publication.

FDA proposes removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list

Event date: 2026-04-30 · Published: 2026-08-09 · Discovered: on/around event date · Last updated: 2026-08-09

A proposed rule would formally exclude the three GLP-1s from the list of bulk substances outsourcing facilities may compound without patient-specific prescriptions — converting post-shortage enforcement posture into regulation for the 503B lane. The patient-specific 503A pathway, under which tracked programs operate, is not the subject of the proposal. Comment-period and finalization status will be tracked here.

Primary sources: Federal Register (proposed rule, April 30, 2026); FDA compounding pages · Change log: 2026-08-09 — initial publication.

FDA approves orforglipron (Foundayo) — first small-molecule GLP-1 pill

Event date: 2026-04-01 · Published: 2026-08-09 · Discovered: on/around event date · Last updated: 2026-08-09

FDA approved orforglipron, branded Foundayo: a once-daily oral GLP-1 with no food, water, or timing restrictions, launched from $149/month self-pay at the lowest dose ($25 with commercial savings cards; ~$50 Medicare Part D copays from July 1). An FDA-approved product at a price inside the compounded semaglutide band changes the outside option for every cash buyer — see the August price check for the current field.

Primary sources: FDA announcement; Eli Lilly launch materials · Change log: 2026-08-09 — initial publication.

FDA approves Wegovy HD — semaglutide 7.2 mg

Event date: 2026-03-19 · Published: 2026-08-09 · Discovered: on/around event date · Last updated: 2026-08-09

FDA approved a 7.2 mg once-weekly semaglutide formulation (Wegovy HD), lifting the labeled ceiling from 2.4 mg and reporting ~20.7% average weight reduction in STEP-UP — narrowing the on-label gap to tirzepatide without a direct top-dose trial. NovoCare self-pay listed the tier at $399. Label reports at the top dose include altered skin sensation. Context: tirzepatide vs semaglutide in 2026.

Primary sources: FDA approval records (March 19, 2026); Novo Nordisk announcements; STEP-UP topline. · Change log: 2026-08-09 — initial publication.

Zepbound KwikPens reach retail pharmacies at LillyDirect self-pay tiers

Event date: 2026-03-16 · Published: 2026-08-09 · Discovered: on/around event date · Last updated: 2026-08-09

Eli Lilly extended its $299–$449 self-pay tiers to Zepbound KwikPens at retail counters, including Walmart. For compounded-market shoppers this matters as context: the FDA-approved comparison price became a same-day retail option — the benchmark our compounded-vs-brand analysis prices against, without ever ranking the two categories together.

Primary sources: Eli Lilly announcements; retail availability listings · Change log: 2026-08-09 — initial publication.

Hims & Hers closes compounded GLP-1s to new patients

Event date: 2026-03-09 · Published: 2026-08-09 · Discovered: on/around event date · Last updated: 2026-08-09

The largest telehealth brand in weight care stopped new-patient enrollment in compounded GLP-1s and moved new starts to brand-name fulfillment — the clearest market signal of the post-shortage contraction this site's shortage-resolution explainer describes. Existing tracked programs continue under the patient-specific 503A pathway.

Primary sources: company announcement; contemporaneous coverage · Change log: 2026-08-09 — initial publication.

FDA issues a coordinated wave of warning letters over compounded GLP-1 marketing

Event date: 2026-02-19 · Published: 2026-08-09 · Discovered: on/around event date · Last updated: 2026-08-09

FDA sent roughly thirty warning letters to telehealth companies and sellers concerning the marketing of compounded GLP-1 drugs — approval-implying language, equivalence claims, and safety-and-efficacy assertions borrowed from approved products. The action addressed claims, not a product-quality finding against any single program; our enforcement explainer and 483-vs-warning-letter guide cover how to read letters like these.

Primary sources: FDA warning-letter database · Change log: 2026-08-09 — initial publication.

TrumpRx lists Zepbound and Wegovy around $350

Event date: 2026-02 · Published: 2026-08-09 · Discovered: on/around event date · Last updated: 2026-08-09

The federal direct-purchase channel began listing both flagship obesity injectables at roughly $350/month, adding a third self-pay brand route beside LillyDirect ($299–$449 by dose) and NovoCare ($349 flat). For compounded-market shoppers the relevance is the benchmark: the approved-product comparison price most cash buyers face is now $299–$449 — the frame our compounded-vs-brand analysis uses without ever ranking the categories together.

Primary sources: program listings; manufacturer cash-pay program pages · Change log: 2026-08-09 — initial publication.

Oral Wegovy tablet launches at a $149 introductory rate

Event date: 2026-01 (approval 2025-12) · Published: 2026-08-09 · Discovered: on/around event date · Last updated: 2026-08-09

Novo Nordisk's oral semaglutide tablet — approved in December 2025 — reached the market in early 2026 with a $149/month introductory self-pay rate, putting an FDA-approved GLP-1 inside the compounded semaglutide price band for the first time. The tablet carries strict empty-stomach dosing rules; its price and the later Foundayo launch together form the brand context the August price check now benchmarks against.

Primary sources: FDA approval records (December 2025); Novo Nordisk launch and program materials · Change log: 2026-08-09 — initial publication.